Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a product containing beta-mannanase produced by a non-genetically modified strain of Aspergillus niger (CBS 120604). The commercial name is Nutrixtend Optim and it is intended to be used as a zootechnical feed additive for all poultry for fattening. Based on a tolerance trial in chickens for fattening and the no observed adverse effect level identified in a subchronic oral toxicity study in rats, the additive was considered safe for all poultry for fattening. The Panel concluded that the use of the product as a feed additive does not give rise to concerns for consumers and the environment. The additive is considered an irritant to skin and eyes and a dermal sensitiser. Due to the proteinaceous nature of the active substance, it is also considered a respiratory sensitiser. The Panel concludes that the additive has the potential to be efficacious as a zootechnical additive at the level of inclusion in feed of chickens for fattening of 30 U beta-mannanase/kg complete feed. This conclusion was extrapolated to all poultry for fattening.

Safety and efficacy of a feed additive consisting of β-mannanase produced by Aspergillus nigerCBS 120604 (Nutrixtend Optim) for use in all poultry for fattening (Kerry Ingredients & Flavours Ltd) / V. Bampidis, G. Azimonti, M.D.L. Bastos, H. Christensen, B. Dusemund, M. Durjava, M. Kouba, M. López-Alonso, S. López Puente, F. Marcon, B. Mayo, A. Pechová, M. Petkova, F. Ramos, Y. Sanz, R.E. Villa, R. Woutersen, G. Martelli, L. Tosti, M. Anguita, Y. García-Cazorla, E. Pettenati, J. Ortuño. - In: EFSA JOURNAL. - ISSN 1831-4732. - 21:6(2023 Jun), pp. e08045.1-e08045.13. [10.2903/j.efsa.2023.8045]

Safety and efficacy of a feed additive consisting of β-mannanase produced by Aspergillus nigerCBS 120604 (Nutrixtend Optim) for use in all poultry for fattening (Kerry Ingredients & Flavours Ltd)

R.E. Villa;L. Tosti;
2023

Abstract

Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a product containing beta-mannanase produced by a non-genetically modified strain of Aspergillus niger (CBS 120604). The commercial name is Nutrixtend Optim and it is intended to be used as a zootechnical feed additive for all poultry for fattening. Based on a tolerance trial in chickens for fattening and the no observed adverse effect level identified in a subchronic oral toxicity study in rats, the additive was considered safe for all poultry for fattening. The Panel concluded that the use of the product as a feed additive does not give rise to concerns for consumers and the environment. The additive is considered an irritant to skin and eyes and a dermal sensitiser. Due to the proteinaceous nature of the active substance, it is also considered a respiratory sensitiser. The Panel concludes that the additive has the potential to be efficacious as a zootechnical additive at the level of inclusion in feed of chickens for fattening of 30 U beta-mannanase/kg complete feed. This conclusion was extrapolated to all poultry for fattening.
digestibility enhancers; efficacy; poultry for fattening; safety; zootechnical additives; β‐Mannanase
Settore BIO/14 - Farmacologia
Settore VET/07 - Farmacologia e Tossicologia Veterinaria
Settore MED/44 - Medicina del Lavoro
giu-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
EFSA Journal - 2023 - - Safety and efficacy of a feed additive consisting of ‐mannanase produced by Aspergillus niger CBS.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.07 MB
Formato Adobe PDF
1.07 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1009688
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact